Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.

Docket No. 13-854

QUESTION PRESENTED:

Whether a district court's factual finding in support of its construction of a patent claim term may be reviewed de novo, as the Federal Circuit requires (and as the panel explicitly did in this case), or only for clear error, as Rule 52(a) requires.

Advertisement